Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition

in response to

Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition

Nextblockbuster

posted on Mar 03, 2017 02:07PM

I guess one could say that. However, the point of the phase I dose escalation trial was by definition to escalate the dose until an unacceptable number adverse events appeared. Now that they've found the maximally tolerated dose in Phase 1, they will soon (hopefully) proceed with Phase 2.